Results 241 to 250 of about 15,278 (270)
Some of the next articles are maybe not open access.
Editorial: acid suppression with potassium‐competitive acid blockers dismissing genotype concerns
Alimentary Pharmacology & Therapeutics, 2020LINKED CONTENT This article is linked to Hwang et al and Hwang & Lee papers.
Carmelo Scarpignato, Richard H. Hunt
openaire +2 more sources
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders
Alimentary Pharmacology & Therapeutics, 2021SummaryBackgroundPotassium‐competitive acid blockers (P‐CABs) are a novel group of acid‐suppressing medicines for the management of acid‐related disorders.AimsTo review published clinical pharmacology studies and clinical trials of P‐CABs.MethodsWe conducted a comprehensive literature search including Medline (PubMed), EMBASE, Web of Science and the ...
Yousef Abdel‐Aziz +2 more
openaire +2 more sources
Potassium-competitive acid blockers and acid-related disorders
Current Opinion in Endocrinology, Diabetes & ObesityPurpose of review Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders. Recent findings
Kevin Z, Huang, H Christian, Weber
openaire +2 more sources
Potassium-competitive acid blockers
Current Opinion in GastroenterologyPurpose of review Acid suppression is the mainstay of management of common foregut disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori infection. Drawbacks of standard management with proton pump inhibitors (PPIs) include acid lability requiring enteric coating, slow onset ...
Trevor A. Davis, C. Prakash Gyawali
openaire +1 more source
Long-term potassium-competitive acid blockers administration causes microbiota changes in rats
Surgical Endoscopy, 2023Vonoprazan is a new potassium-competitive acid blocker (P-CAB) that was recently approved by the FDA. It is associated with a fast onset of action and a longer acid inhibition time. Vonoprazan-containing therapy for helicobacter pylori eradication is highly effective and several studies have demonstrated that a vonoprazan-antibiotic regimen affects gut
Haythem Najah +10 more
openaire +2 more sources
Alimentary Pharmacology & Therapeutics, 2020
LINKED CONTENT This article is linked to Hwang et al and Scarpignato & Hunt papers.
Jun Gi Hwang, SeungHwan Lee
openaire +2 more sources
LINKED CONTENT This article is linked to Hwang et al and Scarpignato & Hunt papers.
Jun Gi Hwang, SeungHwan Lee
openaire +2 more sources
Potassium-competitive acid blocker.
Nihon rinsho. Japanese journal of clinical medicine, 2019Although the first-line medicine for the treatment of reflux esophagitis (RE) is proton. pomp inhibitor(PPI), the effectiveness is affected by the internal metabolism of PPI, the polymor- phism of metabolized enzyme for PPI, the presence of H. pyloi infection or esophageal hernia, and the grade of RE. Recent study indicates that about 30 % of severe RE
Ken, Haruma +3 more
openaire +1 more source
Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease
Digestion, 2018Background: The present study examined the pathogenesis of potassium-competitive acid blocker (P-CAB)-resistant non-erosive reflux disease (NERD). Methods: Forty-three patients with NERD, who had persistent reflux symptoms despite the administration of P-CAB, were included in this study.
Noriyuki, Kawami +7 more
openaire +2 more sources
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
Advances in Therapy, 2016Proton pump inhibitors (PPIs) are widely prescribed as first-line therapy for the treatment of acid-related diseases, such as peptic ulcers and gastro-esophageal reflux disease, and for the eradication of Helicobacter pylori. However, the therapeutic efficacy of conventional PPIs is considered limited because: (1) they are unstable under acidic ...
Kazuyoshi, Otake +8 more
openaire +2 more sources
Editorial: potassium‐competitive acid blockers—is there a role for more complete acid suppression?
Alimentary Pharmacology & Therapeutics, 2022LINKED CONTENTThis article is linked to Chen et al papers.
openaire +2 more sources